Algenix, Inc.

St. Paul, MN 55108

SBIR Award Summary

Total Number of Awards 5
Total Value of Awards $1.08MM
First Award Date 09/30/98
Most Recent Award Date 07/15/02

Key Personnel

Last Name Name Awards Contact
Ruiz Leonard P Ruiz 5

5 Awards Won

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 07/15/02 - 01/31/03

Description (provided by applicant): The liver is the most important organ in metabolizing xenobiotics and drugs. Liver cells (hepatocytes) are used frequently in testing drug metabolism and hepatotoxicity. Hepatocytes in culture can form spheroids that exhibit higher liver-specific functions and sustain high viability longer in culture. This pr...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/01 - 09/29/02

DESCRIPTION (Adapted from the Investigator's Abstract): Algenix, Inc. is taking a bioartificial liver (BAL) developed at the University of Minnesota through a Phase I clinical trial. This bioartificial liver is intended for providing a temporary support to liver failure patients awaiting transplantation. The BAL employs...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 08/01/01 - 12/31/02

DESCRIPTION (Adapted from the Investigator's Abstract): Liver failure is a major cause of death in the U.S. There is a great need for a liver assist device for temporary support of liver failure patients. Algenix is developing a bioartificial liver to meet this critical need. As the first generation enters clinica...

Phase 2 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/00 - 09/29/01

DESCRIPTION (Adapted from the Investigator's Abstract): Algenix, Inc. is taking a bioartificial liver (BAL) developed at the University of Minnesota through a Phase I clinical trial. This bioartificial liver is intended for providing a temporary support to liver failure patients awaiting transplantation. The BAL employs...

Phase 1 SBIR

Agency: Department of Health & Human Services
Topic:
Budget: 09/30/98 - 06/30/00

Algenix, Inc. is taking a bioartificial liver (BAL) developed at the University of Minnesota through a Phase I clinical trial. This bioartificial liver is intended for providing a temporary support to liver failure patients awaiting transplantation. The BAL employs porcine hepatocytes ent...